

1 **Genomic insights into the rapid emergence and evolution of multidrug-**
2 **resistance in *Staphylococcus pseudintermedius***

3
4 Alex J. McCarthy,^{1a} Ewan M. Harrison,² Kinga Stanczak-Mrozek,¹ Bernadette Leggett,³ Andrew
5 Waller,⁴ Mark A. Holmes,² David H. Lloyd,⁵ Jodi A. Lindsay,¹ Anette Loeffler^{5*}

6
7 ^{1a}Institute of Infection and Immunity, St. George's, University of London, London, UK

8 ²Department of Veterinary Medicine, University of Cambridge, Cambridge, UK

9 ³Pathobiology Unit, University Veterinary Hospital, School of Veterinary Medicine, University
10 College Dublin, Dublin, Ireland

11 ⁴Centre of Preventive Medicine, Animal Health Trust, Newmarket, UK

12 ⁵Veterinary Clinical Sciences and Services, Royal Veterinary College, Hawkshead Campus,
13 University of London, London, UK

14

15 Short Title: Multidrug resistant *S. pseudintermedius* emergence

16 Key works: Antimicrobial resistance, horizontal gene transfer, MRSP, whole genome
17 sequencing, zoonotic

^a Current Address: UCL School of Pharmacy, London, UK.

* Corresponding Author Email: aloeffler@rvc.ac.uk, Telephone:+44(0)1707666246 Fax:
+44(0)1707666298

18 Abstract

19 **Objectives:** Multidrug-resistant (MDR), methicillin-resistant *Staphylococcus pseudintermedius*
20 (MRSP) strains have emerged rapidly as major canine pathogens and present serious treatment
21 issues, and concerns to public health due to their, albeit low, zoonotic potential. A further
22 understanding of the genetics of resistance arising from a broadly susceptible background of *S.*
23 *pseudintermedius* is needed.

24 **Methods:** We sequenced the genomes of 12 *S. pseudintermedius* isolates of varied sequence
25 types (ST) and resistance phenotypes.

26 **Results:** Nine distinct clonal lineages had acquired either staphylococcal cassette chromosomes
27 (SCC)*mec* elements and/or Tn5405-like elements carrying up to five resistance genes (*aphA3*,
28 *sat*, *aadE*, *ermB*, *dfrG*) to generate MRSP, MDR-methicillin sensitive *S. pseudintermedius*
29 (MSSP), and MDR-MRSP populations. The most successful and clinically problematic MDR-MRSP
30 clones, ST68 SCC*mecV*(T) and ST71 SCC*mecII-III*, have further accumulated mutations in *gyrA*
31 and *griA* conferring resistance to fluoroquinolones. Carriage of additional mobile genetic
32 elements (MGEs) was highly variable suggesting horizontal gene transfer is frequent in *S.*
33 *pseudintermedius* populations.

34 **Conclusions:** Importantly, the data suggest that MDR-MRSP evolved rapidly by acquisition of a
35 very limited number of MGEs and mutations, and that use of many classes of antimicrobials
36 may co-select for the spread and emergence of MDR and extensively drug resistant strains.

- 37 Antimicrobial stewardship will need to be comprehensive encompassing human medicine and
- 38 veterinary disciplines to successfully preserve antimicrobial efficacy.

39 Introduction

40 Antimicrobial resistance has emerged as one of the most important challenges facing human
41 and veterinary medicine in the 21st century. Animals are major reservoirs for multidrug-
42 resistant (MDR) pathogens including zoonotic bacteria.^{1, 2} Pet animals, in particular, are
43 frequently treated with the same antimicrobial classes that are critical in human medicine,
44 including first and third generation cephalosporins and fluoroquinolones.³ Additionally, pets
45 often have close contact with humans providing opportunities for evolution of resistance on
46 either host with subsequent transmission of bacteria between hosts.⁴⁻⁷

47 *S. pseudintermedius* is a major opportunistic pathogen in dogs and cats that typically causes
48 skin and wound infections.⁸ Methicillin-susceptible *S. pseudintermedius* (MSSP) isolates
49 typically have a widely susceptible phenotype, and infections respond well to treatment with
50 penicillinase-stable β -lactams, lincosamides, fluoroquinolones and potentiated
51 sulphonamides.⁹⁻¹¹ Methicillin-resistant *S. pseudintermedius* (MRSP) isolates carrying *mecA*
52 were first described in 1999,¹² and have since spread clonally across North America, Europe and
53 Asia.¹³⁻¹⁵ MRSP now account for 20%-47% of all clinical *S. pseudintermedius* submissions from
54 dogs and cats in many areas.¹⁶⁻²⁰ More recently, multidrug-resistant (MDR) phenotypes
55 (resistant to four or more antimicrobial classes) have emerged, dramatically limiting treatment
56 options, as often all clinically relevant antimicrobial agents are ineffective. Reports of MDR-
57 MRSP infections in humans have highlighted a threat to human health from zoonotic
58 transmission.²¹⁻²³

59 The genome-wide diversity and the genetic basis underpinning the rapid evolution and
60 accumulation of antibiotic resistance in *S. pseudintermedius* is relatively unknown, despite the
61 sequencing of the genomes of one MDR-MRSP (E140, ST71 SCCmecII-III),²⁶ one MDR-MSSP
62 (ED99, ST25)²⁷ and one MSSP (HKU10-03, ST308).²⁸ Broad β -lactam resistance in MRSP is
63 encoded by *mecA* carried on staphylococcal cassette chromosome (SCC)*mec* elements that
64 have been acquired by multiple *S. pseudintermedius* clonal lineages on multiple independent
65 occasions.²⁹⁻³¹ MDR-MRSP ST68 SCCmecV and MDR-MRSP ST71 SCCmecII-III are the major
66 clones that have spread in North America since 2003-2004 and Europe since 2005-2006,
67 respectively and that continue to disseminate globally.^{14, 15, 32, 32} In this study, we sequenced the
68 genomes of 12 *S. pseudintermedius* isolates in order to characterise the population structure of
69 resistant *S. pseudintermedius*, compare the gene content between major clonal lineages,
70 identify the genetic basis of MDR and explain the evolutionary steps leading to the dominant
71 MDR-MRSP clones.

72 **Methods**

73 **Bacterial isolates**

74 Genomes of 12 *S. pseudintermedius* isolates from canine infections were sequenced (Table 1).
75 Isolates had been confirmed as *S. pseudintermedius* through demonstration of the *S.*
76 *intermedius* group-specific *nuc* by PCR and as MSSP or MRSP by the absence or presence of
77 *mecA*.²⁰ Antimicrobial susceptibility was assessed by disk diffusion tests for penicillin, ampicillin,
78 amoxicillin/clavulanate, cefalexin, oxacillin, fusidic acid, gentamicin, kanamycin, erythromycin,
79 clindamycin, tetracycline, trimethoprim, ciprofloxacin and rifampicin according to BSAC
80 guidelines,³³ resistance to oxacillin according to CLSI guidelines.³⁴ Where breakpoints for a
81 particular antimicrobial agent were not included in these documents, recommendations by the
82 disk manufacturer were used.

83 An isolate was classed as MDR if it was resistant to antimicrobials in ≥ 4 antimicrobial classes.³⁵
84 Amongst MRSPs, the most extensively drug-resistant isolates from our collection of clinical
85 European isolates were selected and for further variation within MRSP ST71, we selected
86 isolates from the UK and from Germany and those with tetracycline resistance and those
87 without. A MDR ST68 isolates was included to allow comparison of the current two most
88 successful lineages and two usual clinical MRSPs were included for their lack of MDR phenotype
89 as they were thought to provide information into the evolutionary events of MDR-MRSP
90 emergence (Table 1). Three MSSPs were selected on varying resistance phenotypes including
91 two MDR-MSSP isolates with uncharacterised STs, and one MSSP with an uncharacterised ST.
92 For PCR reactions, genomic DNA was extracted from overnight cultures grown in brain heart

93 infusion broth (Sigma, UK) using the PureElute Bacterial Genomic DNA preparation kit
94 (EdgeBiosystems, UK) at quarter scale following the standard protocol with the addition of 3µl
95 lysostaphin (5mg/mL, Sigma, UK) to the spheroblast buffer.

96 **Genome sequencing**

97 Overnight cultures were grown in tryptic soy broth (TSB) at 37°C with 200 rpm shaking.
98 Genomic DNA was extracted from 1 mL of cultures using the MasterPure Gram Positive DNA
99 Purification Kit (Cambio, UK). This kit is recommended for extraction of total DNA for whole
100 genome sequencing and has been used in a large number of studies including those assessing
101 low molecular weight molecules such as plasmids.³⁶⁻³⁸ Illumina library preparation was carried
102 out as described.³⁹ Hi-seq sequencing was carried out following the manufacturer's standard
103 protocols (Illumina, Inc, USA). Genomes were assembled *de novo* with Velvet,⁴⁰ which yielded
104 on average 135 contigs/genome (Table 1) and contigs were realigned using Mauve⁴¹ against
105 genome ED99 (Accession: CP002478). Sequencing of the twelve isolates yielded an average
106 total of 401,011 Kb per run, corresponding to genome coverage of between 118x and 213x
107 (mean = 151x; Table 1). Nucleotide sequences of the isolates have been deposited in the
108 European Nucleotide Archive (ENA) (<http://www.ebi.ac.uk/ena/>) and accession numbers are
109 shown in Table 1.

110 **Comparative genomics and phylogenetics**

111 Draft genomes were then compared to the three *S. pseudintermedius* high quality genome
112 sequences published before June 2013, ED99, HKU10-03 and E140 (26-28), using the Artemis
113 and ACT genome visualisation tools.^{42,43} MGEs were characterised by BLAST analysis of unique
114 genome regions. Comparative genome figures were created using EasyFig.⁴⁴ Fastq files for the

115 isolates were mapped against the *S. pseudintermedius* genome ED99 using SMALT
116 (www.sanger.ac.uk/smalt) in order to identify single nucleotide polymorphisms (SNPs), as
117 previously described.⁴⁵ SNPs located in MGEs were identified by comparative genomics and
118 removed from the alignment. Regions of potential recombination were also identified and
119 removed from the alignment as previous described.⁴⁶ A maximum likelihood tree was
120 generated from core genome SNPs (the core genome being defined as regions of the
121 chromosome not excluded when MGEs and regions of potential recombination were removed)
122 using RAxML.⁴⁷ Trees were visualized and annotated using Figtree. Insertion sequence finder
123 was used to detect IS elements (www-is.biotoul.fr/). Restriction-enzymes were named
124 according to rebase.neb.com.⁴⁸ CRISPRfinder was used to detect and characterise CRISPR
125 elements (<http://crispr.u-psud.fr/Server/>).⁴⁹

126 **Population structure analysis**

127 The sequence type (ST) of each of the isolates was determined using the recently developed 7-
128 gene multi-locus sequence typing method (MLST)(54). The clonal distribution and relatedness
129 of *S. pseudintermedius* isolates was assessed using all STs in the MLST database at the time of
130 analysis (<http://pubmlst.org/spseudintermedius/>) and eBURST clustering
131 (<http://eburst.mlst.net/>).⁵⁰

132 **Association of MDR phenotype and presence of Tn5405-like elements**

133 The association of the MDR phenotype with the Tn5405-like elements was tested in a further
134 60 MSSP and 52 MRSP isolates from a collection of clinical canine isolates.⁵¹ All strains were
135 grown on brain heart infusion agar (BHIA) overnight, prior to testing antibiotic
136 resistance/susceptibility by growth on BHIA plates containing 0.02mg/mL erythromycin,

137 0.02mg/mL kanamycin, 0.02mg/mL oxacillin, 0.02mg/mL streptothricin or 0.02mg/mL
138 trimethoprim. Genomic DNA was extracted as previously described. The presence of *Tn5405*-
139 like elements was detected by PCR that targeted the transposase gene using forward
140 (5' AAGCGATTCGATGATTTTGC3') and reverse primers (5' CCTGGTTTTAGTTGGCCATT3'). PCR
141 reactions were performed using Bioline MyTaq kit (Bioline, UK) in 50 µL volumes containing 1
142 pmol forward and reverse primer, 1 x buffer, 0.1 units Bioline MyTaq polymerase, 1uL of DNA
143 and dH₂O. Reactions were heated to 95 °C for an initial 2 minutes, followed by 35 cycles of 95
144 °C for 30 seconds, 60 °C for 30 seconds and 72 °C for 30 seconds, followed by of 1 cycle of 72
145 °C for 10 minutes.

146 **Results**

147 **Population structure of *S. pseudintermedius***

148 The 12 study genomes, representing the phenotypic groups MSSP (*n*=1), MRSP (*n*=2), MDR-
149 MSSP (*n*=2) and MDR-MRSP (*n*=7), were compared to previously sequenced *S.*
150 *pseudintermedius* genomes (*n*=3)(Table 1). All genomes were highly similar to each other, and
151 sequence divergence was mainly due to SNPs and presence/absence of short genomic regions,
152 and variation in the presence/absence of MGEs. Reconstruction of the phylogeny using 34,997
153 high-quality SNPs revealed nine clonal lineages (defined as a group of MLST genotypes in which
154 each genotype shares at least five loci in common with another member of the group) amongst
155 the 15 genomes, six of them sequenced for the first time (CC1, CC68, CC258, CC260, CC262 and
156 CC263). (Figure 1). MRSP isolates were distributed over four clonal lineages (CC71, CC68, CC260

157 and CC258), whilst the MDR phenotype (3 MDR-MSSP and 7 MDR-MRSP) was distributed in six
158 (CC25, CC68, CC71, CC258, CC262 and CC263). The six ST71 isolates only differed by 162 SNPs.

159 Clustering of 309 STs in the MLST-7 database using the eBURST program confirmed that MRSP
160 emerged independently in 6/9 major *S. pseudintermedius* clonal lineages (CC1, CC45, CC68,
161 CC71, CC84 and CC258) and in numerous doublet or unlinked STs (Figure 2). MRSP phenotypes
162 existed in the majority of isolates belonging to STs CC45, CC71 and CC258 suggesting that
163 SCCmec acquisition contributes to clonal lineage expansion.

164 **Multidrug resistance was acquired by successful MDR-MRSP clones through a three-** 165 **step accumulation of genomic changes**

166 To understand the evolution of multidrug-resistance in *S. pseudintermedius*, we investigated
167 the presence and absence of resistance genes in the core and accessory genome, characterised
168 their presence on each identified MGE by BLAST analysis and compared their association with
169 resistance phenotype. All phenotypic resistances could be putatively assigned to a genetic
170 determinant in all isolates. Pairwise alignments of *S. pseudintermedius* genomes revealed they
171 are co-linear to each other, and confirmed a stable component of genes found in all strains
172 (Figure S3). MGEs accounted for up to 8% of the genome, providing evidence of extensive MGE
173 acquisition.

174 All methicillin-resistant study strains carried *mecA* on a SCCmec element (Figures 1 and 4). All
175 MDR-MRSP ST71 isolates had a homologous copy of the SCCmecII-III element (29), while the
176 MDR-MRSP ST68 isolate (23929) had a SCCmecV(T) element.¹⁴ The MDR-MRSP ST261 isolate,
177 1726, carried a novel SCCmecIV element that was homologous to an SCCmecIVg element in *S.*
178 *aureus*,⁵² but possessed an additional nine genes. MRSP ST260 isolates carried a novel SCCmec

179 element that shared blocks of homology to both *SCCmecX* and *SCCmecV* (containing a *ccrC*
180 gene), however, it was not possible to obtain its full structure from the sequencing data (data
181 not shown). Pairwise comparison of *SCCmec* element structures showed element divergence
182 giving further support to an independent evolution of MRSP on multiple occasions (Figure 4).

183 Many other resistance genes were located on transposable elements, and all genomes carried
184 at least two transposons or insertion sequence (IS) elements while *tra* genes for conjugative
185 transfer were absent in all (Figure 1).

186 All eleven MDR isolates carried a large transposable element resembling Tn5405-like
187 elements.^{53,54} This element carried up to five antimicrobial resistance genes *aphA3-sat-aadE-*
188 *dfrG-erm(B)* encoding resistance to aminoglycosides (including kanamycin, neomycin and
189 amikacin), streptothricin, trimethoprim and erythromycin and was present in 8/8 MDR-MRSP
190 and 3/3 MDR-MSSP isolates (Figures 1 and 5). Pairwise comparison revealed all Tn5405-like
191 elements were integrated at the same core genome loci. Variation was seen in carriage of *dfrG*
192 and *cat* (Figure 5), truncated versions were found in MDR-MSSP isolates GL118B and ED99, and
193 one was located on a plasmid (GL117B).

194 Screening the larger collection of 60 MSSP and 52 MRSP, Tn5405-like elements were present in
195 8/11 (73%) MDR-MSSP and in all 46 (100%) MDR-MRSP and the MDR phenotype was found in
196 11/60 (18.3%) MSSP isolates and 46/52 (88.5%) MRSP isolates. Carriage of Tn5405-like
197 elements was associated with the MDR phenotype ($p < 0.001$, χ^2 test).

198 Additional resistance genes were present on transposons or IS elements integrated in the core
199 *S. pseudintermedius* genome (Figure 1). The tetracycline resistance gene *tet(M)* was present on

200 Tn5801 and Tn916 elements in three and five genomes, respectively. All but one genome
201 carried at least one *blaZ* gene, encoding resistance to penicillin, either on Tn552 and/or on
202 Tn554-like elements. Finally, the *aac-aph* gene, encoding resistance to gentamicin, was located
203 on IS256 or IS1272 elements in seven and two genomes, respectively. The *cadA* gene, encoding
204 resistance to cadmium, was located on IS431 elements in four genomes.

205 Plasmids do not appear to play a role in the emergence of MRSP. In this study, 12/15 genomes
206 carried the integrated plasmid first described in ED99,²⁷ but this plasmid did not carry any
207 resistance genes. GL117B possessed an additional plasmid with a replication (*rep*) gene with
208 97% homology to plasmid pUB112 from *S. aureus*, and resistance genes *aphA-sat-aadE-ermB*
209 similar to the truncated version of the *Tn5405*-like element (Figure 5). There was no further
210 evidence for the carriage of plasmid replication (*rep*) genes in any of the *S. pseudintermedius*
211 genomes.

212 Of core genome mutations described to confer antimicrobial resistance in *S.*
213 *pseudintermedius*,⁸⁰ individual mutations were present in all strains irrespective of their
214 phenotype. However, only the six isolates phenotypically resistant to fluoroquinolones (all
215 MDR-MRSP ST71 and the MDR-MRSP ST68 isolate), representing the most successful MDR-
216 MRSP clones, had mutations *gyrA* S84L and *grrA* S80I simultaneously (Figure 1). Mutations in
217 *folP* causing sulphamide resistance are described in *S. aureus*.⁵⁷ However, of the eight strains
218 (including ED99) showing phenotypic resistance to trimethoprim/sulfamethoxazole, the
219 clinically relevant combination product available for veterinary use, only one strain (23923)
220 showed *folP* mutations. Instead, *in vitro* resistance was more often correlated with the carriage

221 of *dfgG* on Tn5405-like elements (5/8 strains). Only the successful MDR-MRSP ST68, 23929, was
222 phenotypically resistant to fusidic acid using BSAC breakpoints.³³ In *S. aureus*, *fusA* mutations
223 cause low-level resistance to fusidic acid.^{58, 59} Isolate 23929 had three non-synonymous
224 mutations in *fusA* (A376V, I461V and V90I), while only 1 other strain had a *fusA* mutation
225 (V90I). No strains carried the MGE-encoded *fusB*, *fusC* or *fusD*. This data indicates that
226 mutations at sites 376 and 461 are implicated in phenotypic resistance to fusidic acid.

227 **Comparison of fitness factors in the genomes**

228 The successful survival and spread of MDR-MRSP ST71 and MDR-MRSP ST68 are likely depend
229 on factors that influence colonisation or disease and other fitness factors that might influence
230 survival and evolutionary success were widely distributed (Figure 1). Prophages were present in
231 all *S. pseudintermedius* genomes except ED99, and were integrated into eight chromosomal
232 locations (Figure 1). All MDR-MRSP ST71 isolates possessed three homologous prophages
233 without evidence for loss/acquisition of additional prophages. The MDR-MRSP ST68 isolate
234 possessed four prophages, whilst all other strains possessed only one prophage in their
235 genome. Prophage genomes were diverse, with few shared genes, and chromosome
236 integration sites differed (Figure S1). Genes encoding virulence associated protein E (VirE) and a
237 surface protein with LPxTG motif were located on some prophages, but genes homologous to
238 Panton-Valentine leukocidin (PVL) toxin were not found.

239 *S. pseudintermedius* pathogenicity island (SpPI)1, described in ED99, was present in all genomes
240 except 1726 (Figure 1). SpPI1 variants existed (Figure 1 and Figure S2), but all shared the same
241 integrase gene and the same core genome integration site. Hypothetical proteins were
242 identified but none related to known virulence factors.

243 Potential virulence genes described in *Staphylococcus intermedius* group (SIG) isolates such as
244 surface proteins, exoenzymes and toxins including novel toxins Se-int, the β -hemolysin and
245 exfoliative toxins⁵³ were found in some but not all genomes. Four of 18 genes encoding surface
246 proteins that adhere to extracellular matrix factors (*spsF*, *spsO*, *spsP* and *spsQ*)⁶⁰⁻⁶³ were absent
247 in some genomes (Figure 1). All surface protein genes were variable (non-synonymous and
248 Indel variation) between lineages, with the most variation present in *spsD*, *spsF*, *spsJ*, *spsK*,
249 *spsL*, *spsO* and *spsP*. There was no variation in the surface protein genes within ST71 isolates.
250 Six of the seven exoenzyme genes (*coa*, *lip*, *geh*, *htrA*, *nuc* and *clpX*) were present in all
251 genomes, whereas *nanB* encoding sialidase was present in only 5/15 genomes (Figure 1). Three
252 of the four toxin genes (*hly*, *se-int* and *speta*) were present in all genomes; in contrast *lukF-I*
253 was present in only 9/15 *S. pseudintermedius* genomes (Figure 1). Genes encoding all previously
254 identified two-component regulatory systems (*agrA*, *agrB*, *agrC*, *agrD*, *saeS*, *saeR*, *srrA*, *srrB*,
255 *arlS*, *arlR*, *lytS* and *lytR*) and SarA protein families (*sarA*, *sarR*, *sarZ* and *rot*) were present in all
256 genomes (Figure 1). Collectively, this data indicates that variation in virulence factors in the
257 core genome is common in *S. pseudintermedius*, and possibly lineage-associated as in *S. aureus*.

258 **Barriers to horizontal gene transfer in *S. pseudintermedius***

259 The success of particular lineages and/or clones, such as the major MDR-MRSP clones, may also
260 depend on their ability to acquire novel MGEs through horizontal gene transfer (HGT).
261 Restriction-modification (R-M) systems and competence genes *comG* and *comE* were present in
262 all genomes irrespective of antimicrobial resistance. All isolates showed evidence of a type I R-
263 M system that we therefore call Sps1, and is also known as SpsE140ORFAP (rebase.neb.com). A

264 full intact type I Sps1 R-M system, containing restriction (*hsdR*), modification (*hsdM*) and
265 specificity (*hsdS*) genes, was present in the core genome of 11/15 *S. pseudintermedius* genomes
266 (Figure 1). In contrast, incomplete systems that are predicted to be non-functional were
267 present in the remaining genomes. HKU10-03 (ST308) possessed *hsdR* and *hsdM*, but no *hsdS*,
268 4639949 (ST309) possessed *hsdM* only, whilst ED99 (ST25) and GL118B (ST262) possessed
269 truncated *hsdR* genes. Two types of *hsdS* variant in the type I R-M systems existed, whilst *hsdR*
270 sequences and *hsdM* sequences were highly homologous across all genomes (Figure 1). These
271 data suggest that the two clusters of lineages modify their DNA at different target sites,
272 restricting horizontal transfer of DNA and divergent evolution of *S. pseudintermedius* into at
273 least two populations.⁶⁴ Additionally, a second type I R-M system was carried on all SCCmecII-III
274 elements of MDR-MRSP ST71 genomes and on the SCCmecIV element of the MDR-MRSP ST261
275 genome (Figure 1, Figure 4). The *hsdS*, *hsdM* and *hsdR* sequences from the SCCmec elements
276 were highly homologous, but different from the sequences of respective core genome genes,
277 and has been called SpsE140ORFGP. Predicted intact type II R-M systems, containing *hsdM* and
278 *hsdR* genes were present in 6/15 genomes (Figure 1) at four different locations: (i) adjacent to
279 *orfX* in MDR-MSSP ST25 (ED99)(Sps99ORF30P with a predicted cutsite of CTRYAG) and MSSP
280 ST309 (4639949) genomes, (ii) adjacent to the *phoB* gene in the MSSP ST308 (HKU10-03)
281 (SpsORF2234P with a predicted cutsite of CCNGG) and MRSP ST260 genomes (BNG1 and BNG3),
282 (iii) at the type I R-M system locus in MDR-MRSP ST68 (23929) (called Sps68ORF1551), and (iv)
283 on the SCCmecIV and novel SCCmec elements of MDR-MRSP ST68 (23929) and MRSP ST260
284 (BNG1 and BNG2) genomes (called SpsORF2234P), respectively, and was homologous to the
285 type II system present at the *phoB* site.

286 Clustered regularly interspaced short palindromic repeats (CRISPR) systems were detected in
287 3/15 genomes (Figure 1). Six of the 22 spacers in CRISPR from ED99 were homologous to
288 bacteriophage and plasmids,²⁷ suggesting this isolate is immune to uptake of specific elements
289 encoding these sequences. Two of the 24 spacers in CRISPR from GL118B were homologous to
290 bacteriophage, and 2/13 spacers in the CRISPR system found on SCCmecV(T) in 23929 were
291 homologous to bacteriophage and plasmids. There was no evidence that CRISPR has recognised
292 important SCCmec or transposons and MDR-MRSP ST71 and ST68 did not have greater or fewer
293 R-M or CRISPR systems than other strains.

294 Discussion

295 Identifying the whole genome characteristics of MDR-MRSP is critical to explain the evolution
296 and rapid emergence of successful clones. We have shown that only a three-step accumulation
297 of an SCCmec element, Tn5405-like elements and SNPs in *gyrA/grlA* was required for the
298 emergence of the two globally successful MDR-MRSP clones. At the same time, these MDR-
299 MRSP have successfully spread worldwide, indicating that selection for survival of these
300 resistant isolates is common.

301 Multiple SCCmec elements have now been sequenced in *S. pseudintermedius*.^{26, 29, 68-71} They
302 have given rise to multiple MRSP clones and we now report MRSP phenotypes in six of nine
303 major lineages. The wide distribution of MRSP phenotypes in STs from CC45, CC71 and CC258
304 suggests that SCCmec elements were acquired ancestrally or that these lineages can acquire
305 and spread SCCmec more effectively. SCCmec elements of *S. pseudintermedius* most closely
306 matched SCCmec elements from *S. aureus* (SCCmecII-III, SCCmecIV and SCCmecV(T)) and/or

307 from coagulase-negative staphylococci (CNS) such as *S. epidermidis* (SCCmecII-III) and *S.*
308 *haemolyticus* (Ψ SCCmec₅₇₃₉₅), supporting a role of HGT from CNS in MRSP emergence.

309 The acquisition of the Tn5405-like elements, encoding multiple antimicrobial resistances
310 simultaneously was a consistent feature of the MDR phenotype seen in both MSSP and MRSP.
311 Tn5405-like elements have been acquired by at least four *S. pseudintermedius* lineages, with
312 variants also found in an additional two lineages. Driving pressures for the selection of Tn5405-
313 like elements remain unclear as antimicrobial prescribing data for pets are available for only a
314 few countries and the antimicrobial agents encoded on this element seem of little veterinary
315 clinical relevance. Nevertheless, the use of only one antimicrobial could be sufficient to select
316 for the survival of clones with Tn5405-like transposons and resistance to four classes of
317 antimicrobial. Acquisition of specific *gyrA/grlA* SNPs associated with phenotypic resistance to
318 fluoroquinolones is strongly correlated with the globally successful MDR-MRSP lineages.^{14,69}
319 Several fluoroquinolones were authorised for use in pets and have been widely used since the
320 late 1980s suggesting a key role of fluoroquinolones in promoting survival and spread of MRSP.
321 A similar association has been reported between fluoroquinolone resistance and the pandemic
322 spread of major hospital-associated MRSA clones.^{25, 65, 74}

323 The variation in distribution of other resistance genes and potential fitness factors suggests a
324 genomic plasticity provided by transposons and suggests that HGT of transposons is frequent in
325 *S. pseudintermedius*.^{14, 75-77} Though prophages were present in all genomes (except ED99),
326 MDR-MRSP ST71 and ST68 strains contained most prophages suggesting a potential role of
327 prophages in the fitness of MRSP.

328 Although HGT mechanisms have been poorly studied in *S. pseudintermedius*, the frequent
329 carriage of prophages makes it likely that transfer is predominantly by bacteriophage
330 transduction rather than plasmid conjugation, in contrast to *S. aureus*.^{24, 78} Experimental studies
331 are required to test whether the prophage are capable of performing generalised transduction,
332 and whether transformation occurs in *S. pseudintermedius* strains.

333 The distribution of type I and/or type II R-M systems, known barriers to HGT in *S. aureus*,
334 suggested that MDR-MRSP genomes are no more efficient or inefficient in acquiring MGE-
335 encoded resistance. R-M systems were present on all *SCCmec* elements in this study, and also
336 on Ψ *SCCmec*57395 from a previously described MDR-MRSP ST45.⁶⁹ To determine if populations
337 are evolving independently, future studies could assess the extent of recombination occurring
338 within and between *S. pseudintermedius* populations. As CRISPR systems were rare in genomes,
339 and spacer sequences did not match any known *SCCmec* elements or transposons, it is unlikely
340 that CRISPRs have a major role in governing HGT of resistance genes in *S. pseudintermedius*.
341 Overall, ED99 carried the fewest R-M systems and no prophage, and is potentially an
342 appropriate laboratory strain for genetic manipulation.

343 We conclude that MDR-MRSP evolved rapidly through step-wise accumulation of *SCCmec*,
344 Tn5405-like elements and SNPs conferring fluoroquinolone resistance. Thus, this study
345 indicates that the use of only a small number of antimicrobials may select for the pandemic
346 spread of MDR strains. In particular, a unifying feature of the fittest clones, MDR-MRSP ST68
347 and MDR-MRSP ST71, was their fluoroquinolone resistance through core genome mutations,
348 mirroring the success of hospital-associated MRSA clones, such as MRSA CC22. These findings

349 have implications for public health as they raise concern over additive selection pressure on
350 zoonotic bacteria since antimicrobial classes used in pet animals are the same as those critical
351 in human medicine. Therefore stewardship needs to be comprehensive and include medical
352 and veterinary healthcare in order to successfully preserve antimicrobial efficacy.

353 **Acknowledgements**

354 We thank the core sequencing and informatics team at the Wellcome Trust Sanger Institute for
355 sequencing of the isolates described in this study. The publication made use of the
356 *Staphylococcus pseudintermedius* MLST website (<http://pubmlst.org/spseudintermedius/>)
357 developed by Keith Jolley, curated by Vincent Perreten and sited at the University of Oxford
358 (Jolley & Maiden 2010. BMC Bioinformatics. 11:595). The development of this site has been
359 funded by the Wellcome Trust. We thank Ross Fitzgerald, University of Edinburgh, for providing
360 the ED99 isolate.

361 **Funding**

362 This work was supported by a Royal Veterinary College internal research grant (R.9VPR.LOE) for
363 new lecturers (AL) and supported by a Medical Research Council Partnership grant (EMH, MAH)
364 (G1001787/1).

365 **Transparency declaration**

366 None to declare.

367

368 **References**

- 369 1. Guardabassi L, Schwarz S, Lloyd DH. Pet animals as reservoirs of antimicrobial-resistant
370 bacteria. *J Antimicrob Chemother* 2004; **54**: 321-332.
- 371 2. Prescott JF. Antimicrobial use in food and companion animals. *Anim Health Res Rev*
372 2008; **9**: 127-133.
- 373 3. WHO. 2011. Critically important antimicrobials for human drug. Geneva, *World Health*
374 *Organization*, 2011.
375 (http://apps.who.int/iris/bitstream/10665/77376/1/9789241504485_eng.pdf, accessed 13
376 February 2014).
- 377 4. Manian FA. Asymptomatic nasal carriage of mupirocin-resistant, methicillin-resistant
378 *Staphylococcus aureus* (MRSA) in a pet dog associated with MRSA infection in household
379 contacts. *Clin Infect Dis* 2003; **36**: e26-8.
- 380 5. Guardabassi L, Loeber ME, Jacobson A. Transmission of multiple antimicrobial-resistant
381 *Staphylococcus intermedius* between dogs affected by deep pyoderma and their owners. *Vet*
382 *Microbiol* 2004; **98**: 23-27.
- 383 6. van Duijkeren E, Wolfhagen MJ, Heck ME *et al*. Transmission of a Pantone-Valentine
384 leucocidin-positive, methicillin-resistant *Staphylococcus aureus* strain between humans and a
385 dog. *J Clin Microbiol* 2005; **43**: 6209-6211.
- 386 7. van Duijkeren E, Kamphuis M, van der Mije IC *et al*. Transmission of methicillin-
387 resistant *Staphylococcus pseudintermedius* between infected dogs and cats and contact pets,
388 humans and the environment in households and veterinary clinics. *Vet Microbiol* 2011; **150**:
389 338-343.

- 390 8. Bond R, Loeffler A. What's happened to *Staphylococcus intermedius*? Taxonomic
391 revision and emergence of multi-drug resistance. *J Small Anim Pract* 2012; **53**: 147-154.
- 392 9. Pellerin JL, Bourdeau P, Sebbag H *et al.* Epidemiosurveillance of antimicrobial compound
393 resistance of *Staphylococcus intermedius* clinical isolates from canine pyodermas. *Comp*
394 *Immunol Microbiol Infect Dis* 1998; **21**: 115-133.
- 395 10. Medleau L, Long RE, Brown J *et al.* Frequency and antimicrobial susceptibility of
396 *Staphylococcus* species isolated from canine pyoderma. *Am J Vet Res* 1986; **47**: 229-231.
- 397 11. Lloyd DH, Lamport AI, Feeney C. Sensitivity to antibiotics amongst cutaneous and
398 mucosal isolates of canine pathogenic staphylococci in the UK, 1980–96. *Vet Dermatol* 1996; **7**:
399 171-175.
- 400 12. Gortel K, Campbell KL, Kakoma I *et al.* Methicillin resistance among staphylococci
401 isolated from dogs. *Am J Vet Res* 1999; **60**: 1526-1530.
- 402 13. Chanchaithong P, Perreten V, Schwendener S *et al.* Strain typing and antimicrobial
403 susceptibility of methicillin-resistant coagulase-positive staphylococcal species in dogs and
404 people associated with dogs in Thailand. *J Appl Microbiol* 2014; **117**: 572-586.
- 405 14. Perreten V, Kadlec K, Schwarz S *et al.* 2010. Clonal spread of methicillin-resistant
406 *Staphylococcus pseudintermedius* in Europe and North America: an international multicentre
407 study. *J Antimicrob Chemother* 2010; **65**: 1145-1154.
- 408 15. Ruscher C, Lübke-Becker A, Semmler T *et al.* Widespread rapid emergence of a distinct
409 methicillin- and multidrug-resistant *Staphylococcus pseudintermedius* (MRSP) genetic lineage in
410 Europe. *Vet Microbiol* 2010; **144**: 340-346.

- 411 16. Beck KM, Waisglass SE, Dick HL *et al.* Prevalence of methicillin-resistant *Staphylococcus*
412 *pseudintermedius* (MRSP) from skin and carriage sites of dogs after treatment of their
413 methicillin-resistant or methicillin-sensitive staphylococcal pyoderma. *Vet Dermatol* 2012; **23**:
414 369-375
- 415 17. Bryan J, Frank LA, Rohrbach BW, Burgette LJ, Cain CL, Bemis DA. Treatment outcome of
416 dogs with methicillin-resistant and methicillin-susceptible *Staphylococcus pseudintermedius*
417 pyoderma. *Vet Dermatol* 2012; **23**: 361-368.
- 418 18. Feng Y, Tian W, Lin D *et al.* Prevalence and characterization of methicillin-resistant
419 *Staphylococcus pseudintermedius* in pets from South China. *Vet Microbiol* 2012; **160**: 517-524.
- 420 19. De Lucia M, Moodley A, Latronico F *et al.* Prevalence of canine methicillin resistant
421 *Staphylococcus pseudintermedius* in a veterinary diagnostic laboratory in Italy. *Res Vet Sci*
422 2011; **91**: 346-348.
- 423 20. Loeffler A, Linek M, Moodley A *et al.* First report of multiresistant, *mecA*-positive
424 *Staphylococcus intermedius* in Europe: 12 cases from a veterinary dermatology referral clinic in
425 Germany. *Vet Dermatol* 2007; **18**: 412-421.
- 426 21. Savini V, Barbarini D, Polakowska K *et al.* Methicillin-resistant *Staphylococcus*
427 *pseudintermedius* infection in a bone marrow transplant recipient. *J Clin Microbiol* 2013; **51**:
428 1636-1638.
- 429 22. Soedarmanto I, Kanbar T, Ülbegi-Mohyla H *et al.* Genetic relatedness of methicillin-
430 resistant *Staphylococcus pseudintermedius* (MRSP) isolated from a dog and the dog owner. *Res*
431 *Vet Sci* 2011; **91**: e25-7.

- 432 23. Stegmann R, Burnens A, Maranta CA *et al.* Human infection associated with
433 methicillin-resistant *Staphylococcus pseudintermedius* ST71. *J Antimicrob Chemother* 2010; **65**:
434 2047-2048.
- 435 24. Lindsay JA. *Staphylococcus aureus* genomics and the impact of horizontal gene transfer.
436 *Int J Med Microbiol* 2014; **304**: 103-109.
- 437 **25.** Knight GM, Budd EL, Whitney L *et al.* Shift in dominant hospital-associated methicillin-
438 resistant *Staphylococcus aureus* (HA-MRSA) clones over time. *J Antimicrob Chemother* 2012; **67**:
439 2514-2522.
- 440 26. Moodley A, Riley MC, Kania SA *et al.* Genome sequence of *Staphylococcus*
441 *pseudintermedius* strain E140, an ST71 European-associated methicillin-resistant isolate.
442 *Genome Announc* 2013; **1**: e0020712.
- 443 27. Ben Zakour NL, Bannoehr J, van den Broek AH *et al.* Complete genome sequence of
444 the canine pathogen *Staphylococcus pseudintermedius*. *J Bacteriol* 2011; **193**: 2363-2364.
- 445 28. Tse H, Tsoi HW, Leung SP *et al.* Complete genome sequence of the veterinary
446 pathogen *Staphylococcus pseudintermedius* strain HKU10-03, isolated in a case of canine
447 pyoderma. *J Bacteriol* 2011; **193**: 1783-1784.
- 448 29. Descloux S, Rossano A, Perreten V. Characterization of new staphylococcal cassette
449 chromosome *mec* (SCC*mec*) and topoisomerase genes in fluoroquinolone- and methicillin-
450 resistant *Staphylococcus pseudintermedius*. *J Clin Microbiol* 2008; **46**: 1818-1823.
- 451 30. Bannoehr J, Ben Zakour NL, Waller AS *et al.* Population genetic structure of the
452 *Staphylococcus intermedius* group: insights into *agr* diversification and the emergence of
453 methicillin-resistant strains *J Bacteriol* 2007; **189**: 8685-8692.

- 454 31. Sasaki T, Kikuchi K, Tanaka Y *et al.* Reclassification of phenotypically identified
455 *Staphylococcus intermedius* strains. *J Clin Microbiol* 2007; **45**: 2770-2278.
- 456 32. Quitoco IM, Ramundo MS, Silva-Carvalho MC *et al.* First report in South America of
457 companion animal colonization by the USA100 clone of community-acquired methicillin-resistant
458 *Staphylococcus aureus* (ST30) and by the European clone of methicillin-resistant *Staphylococcus*
459 *pseudintermedius* (ST71). *BMC Res Notes* 2013; **6**: 336.
- 460 33. Andrews JM, BSAC Working Party on Susceptibility Testing. BSAC standardized disc
461 susceptibility testing method (version 7). *J Antimicrob Chemother* 2008; **62**: 256-278.
- 462 34. CLSI (Clinical and Laboratory Standards Institute) Performance standards for
463 antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved
464 standard-fourth edition- and second informational supplement. CLSI documents VET01-A4 and
465 VET01-S2. Wayne, PA: Clinical and Laboratory Standards Institute 2013.
- 466 35. Magiorakos AP, Srinivasan A, Carey RB *et al.* Multidrug-resistant, extensively drug-
467 resistant and pandrug-resistant bacteria: an international expert proposal for interim standard
468 definitions for acquired resistance. *Clin Microbiol Infect* 2012; **18**: 268-281.
- 469 36. Iatsenko I, Corton C, Pickard DJ *et al.* Draft genome sequence of highly nematocidal
470 *Bacillus thuringiensis* DB27. *Genome Announc* 2014; **2**: e00101-14.
- 471 37. Harrison EM, Weinert LA, Holden MT *et al.* A shared population of epidemic methicillin-
472 resistant *Staphylococcus aureus* 15 circulates in humans and companion animals. *mBio* 2014; **5**:
473 e00985-00913.

- 474 38. Wright MS, Haft DH, Harkins DM *et al.* New insights into dissemination and variation of
475 the health care-associated pathogen *Acinetobacter baumannii* from genomic analysis. *mBio*
476 2014; **5**: e00963-13.
- 477 39. Quail MA, Kozarewa I, Smith F *et al.* A large genome center's improvements to the
478 Illumina sequencing system. *Nat Methods* 2008; **5**: 1005-1010.
- 479 40. Zerbino DR, Birney E. Velvet: algorithms for *de novo* short read assembly using de Bruijn
480 graphs. *Genome Res* 2008; **18**: 821-829.
- 481 41. Darling ACE, Mau B, Blattner FR *et al.* Mauve: Multiple Alignment of Conserved Genomic
482 Sequence With Rearrangements. *Genome Res* 2004; **14**: 1394-1403.
- 483 42. Carver TJ, Rutherford KM, Berriman M *et al.* ACT: the Artemis Comparison Tool.
484 *Bioinformatics* 2005; **21**: 3422-3423.
- 485 43. Rutherford K, Parkhill J, Crook J *et al.* Artemis: sequence visualization and annotation.
486 *Bioinformatics* 2000; **16**: 944-945.
- 487 44. Sullivan MJ, Petty NK, Beatson SA. Easyfig: a genome comparison visualizer.
488 *Bioinformatics* 2011; **27**: 1009-1010.
- 489 45. Koser CU, Holden MTG, Ellington MJ *et al.* Rapid whole-genome sequencing for
490 investigation of a neonatal MRSA outbreak. *N Engl J Med* 2012; **366**: 2267-2275.
- 491 46. Croucher NJ, Harris SR, Fraser C *et al.* Rapid pneumococcal evolution in response to
492 clinical interventions. *Science* 2011; **331**: 430-434.
- 493 47. Stamatakis AT, Ludwig T, Meier H RAxML-III: a fast program for maximum likelihood-
494 based inference of large phylogenetic trees. *Bioinformatics* 2005; **21** :456-463.
- 495 48. Roberts RJ, Belfort M, Bestor T *et al.* A nomenclature for restriction enzymes, DNA

496 methyltransferases, homing endonucleases and their genes. *Nucleic Acids Res* 2003; **31**: 1805-
497 12.

498 49. Grissa I, Vergnaud G, Pourcel C. CRISPRFinder: a web tool to identify clustered
499 regularly interspaced short palindromic repeats. *Nucleic Acids Res* 2007; **35**(Web Server issue):
500 W52-57.

501 50. Feil EJ, Li BC, Aanensen DM, Hanage WP. eBURST: inferring patterns of evolutionary
502 descent among clusters of related bacterial genotypes from multilocus sequence typing data. *J*
503 *Bacteriol* 2004; **186**: 1518-1530.

504 51. Lehner G, Linek M, Bond R *et al.* Case-control risk factor study of methicillin-resistant
505 *Staphylococcus pseudintermedius* (MRSP) infection in dogs and cats in Germany. *Vet Microbiol*
506 2014; **168**: 154-160.

507 52. Kwon NH, Park KT, Moon JS. *Staphylococcal cassette chromosome mec* (SCCmec)
508 characterization and molecular analysis for methicillin-resistant *Staphylococcus aureus* and
509 novel SCCmec subtype IVg isolated from bovine milk in Korea. *J Antimicrob Chemother* 2005;
510 **56**: 624-632.

511 **53.** Ben Zakour NL, Beatson SA, van den Broek AH *et al.* Comparative genomics of the
512 *Staphylococcus intermedius* group of animal pathogens. *Front Cell Infect Microbiol* 2012; **2**: 44.

513 54. Gómez-Sanz E, Torres C, Lozano C *et al.* Detection and characterization of methicillin-
514 resistant *Staphylococcus pseudintermedius* in healthy dogs in La Rioja, Spain. *Comp Immunol*
515 *Microbiol Infect Dis* 2013; **34**: 447-453.

516 55. Intorre L, Vanni M, Di Bello D *et al.* Antimicrobial susceptibility and mechanism of
517 resistance to fluoroquinolones in *Staphylococcus intermedius* and *Staphylococcus schleiferi*. *J*

518 *Vet Pharmacol Ther* 2007; **30**: 464-469.

519 56. Noguchi N, Okihara T, Namiki Y *et al.* Susceptibility and resistance genes to
520 fluoroquinolones in methicillin-resistant *Staphylococcus aureus* isolated in 2002. *Int J*
521 *Antimicrob Agents* 2005; **25**: 374-379.

522 57. Hampele IC, D’Arcy A, Dale GE *et al.* Structure and function of the dihydropteroate
523 synthase from *Staphylococcus aureus*. *J Mol Biol* 1997; **268**: 21-30.

524 58. Besier S, Ludwig A, Brade V *et al.* Molecular analysis of fusidic acid resistance in
525 *Staphylococcus aureus*. *Mol Microbiol* 2003; **47**: 463-469.

526 59. Nagaev I, Björkman J, Andersson DI *et al.* Biological cost and compensatory evolution in
527 fusidic acid-resistant *Staphylococcus aureus*. *Mol Microbiol* 2001; **40**: 433-439.

528 60. Pietrocola G, Geoghegan JA, Rindi S *et al.* Molecular characterization of the multiple
529 interactions of SpsD, a surface protein from *Staphylococcus pseudintermedius*, with host
530 extracellular matrix proteins. *PLoS One*. 2013; **8**:e66901.

531 61. Bannoehr J, Brown JK, Shaw DJ *et al.* *Staphylococcus pseudintermedius* surface proteins
532 SpsD and SpsO mediate adherence to *ex vivo* canine corneocytes. *Vet Dermatol* 2012; **23**: 119-
533 124.

534 62. Bannoehr J, Ben Zakour NL, Reglinski M *et al.* Genomic and surface proteomic analysis of
535 the canine pathogen *Staphylococcus pseudintermedius* reveals proteins that mediate adherence
536 to the extracellular matrix. *Infect Immun* 2011; **79**: 3074-3086.

537 63. Geoghegan JA, Smith EJ, Speziale P *et al.* *Staphylococcus pseudintermedius* expresses
538 surface proteins that closely resemble those from *Staphylococcus aureus*. *Vet Microbiol* 2009;
539 **138**: 345-352.

- 540 64. Roberts GA, Houston PJ, White JH *et al.* Impact of target site distribution for Type I
541 restriction enzymes on the evolution of methicillin-resistant *Staphylococcus aureus* (MRSA)
542 populations. *Nucleic Acids Res* 2013; **41**: 7472-7484.
- 543 65. Holden MTG, Hsu LY, Kurt K *et al.* A genomic portrait of the emergence, evolution, and
544 global spread of a methicillin-resistant *Staphylococcus aureus* pandemic. *Genome Res* 2013; **23**:
545 653-664.
- 546 66. Mather AE, Reid SW, Maskell DJ *et al.* Distinguishable epidemics of multidrug-resistant
547 *Salmonella typhimurium* DT104 in different hosts. *Science* 2013; **341**: 1514-1517.
- 548 67. Mutreja A, Kim DW, Thomson NR *et al.* Evidence for several waves of global
549 transmission in the seventh cholera pandemic. *Nature* 2011; **477**: 462-465.
- 550 68. Black CC, Solyman SM, Eberlein LC *et al.* Identification of a predominant multilocus
551 sequence type, pulsed-field gel electrophoresis cluster, and novel staphylococcal chromosomal
552 cassette in clinical isolates of *mecA*-containing, methicillin-resistant *Staphylococcus*
553 *pseudintermedius*. *Vet Microbiol* 2009; **139**: 333-338.
- 554 69. Perreten V, Chanchaithong P, Prapasarakul N *et al.* Novel pseudo-staphylococcal
555 cassette chromosome *mec* element (ψ SCCmec57395) in methicillin-resistant *Staphylococcus*
556 *pseudintermedius* CC45. *Antimicrob Agents Chemother* 2013; **57**: 5509-5515.
- 557 70. Solyman SM, Black CC, Duim B *et al.* Multilocus sequence typing for characterization of
558 *Staphylococcus pseudintermedius*. *J Clin Microbiol* 2013; **51**: 306-310.
- 559 71. Youn JH, Moodley A, Park YH *et al.* Genome sequence of methicillin-resistant
560 *Staphylococcus pseudintermedius* Sequence Type 233 (ST233) Strain K7, of Human Origin.
561 *Genome Announc* 2013; **1**. pii:e00310-13.

- 562 72. Hung WC, Takano T, Higuchi W *et al.* Comparative genomics of community-acquired
563 ST59 methicillin-resistant *Staphylococcus aureus* in Taiwan: novel mobile resistance structures
564 with IS1216V. *PLoS One* 2012; **7**:e46987.
- 565 73. Werner G, Hildebrandt B, Witte W. Linkage of *erm(B)* and *aadE-sat4-aphA-3* in multiple-
566 resistant *Enterococcus faecium* isolates of different ecological origins. *Microb Drug Resist* 2003;
567 Suppl **1**: S9-16.
- 568 74. Hori S, Sunley R, Tami A *et al.* The Nottingham *Staphylococcus aureus* population study:
569 prevalence of MRSA among the elderly in a university hospital. *J Hosp Infect* 2002; **50**: 25-29.
- 570 75. Rota A, Milani C, Corrà M *et al.* Misuse of antimicrobials and selection of methicillin-
571 resistant *Staphylococcus pseudintermedius* strains in breeding kennels: genetic characterization
572 of bacteria after a two-year interval. *Reprod Domest Anim* 2013; **48**: 1-6.
- 573 76. Nienhoff U, Kadlec K, Chaberny IF *et al.* Methicillin-resistant *Staphylococcus*
574 *pseudintermedius* among dogs admitted to a small animal hospital. *Vet Microbiol* 2011; **150**:
575 191-197.
- 576 77. Kadlec K, Schwarz S, Perreten V *et al.* Molecular analysis of methicillin-resistant
577 *Staphylococcus pseudintermedius* of feline origin from different European countries and North
578 America. *J Antimicrob Chemother* 2010; **65**: 1826-1828.
- 579 78. McCarthy AJ, Witney AA & Lindsay JA. *Staphylococcus aureus* temperate bacteriophage:
580 carriage and horizontal gene transfer (HGT) is lineage associated. *Front Cell Infect Microbiol*
581 2012; **2**: 6.
- 582 79. Ito T, Ma XX, Takeuchi F *et al.* Novel type V staphylococcal cassette chromosome *mec*
583 driven by a novel cassette chromosome recombinase, *ccrC*. *Antimicrob Agents Chemother* 2004;

584 **48:** 2637-2651.

585 80. Kadlec K, Schwarz S. Antimicrobial resistance of *Staphylococcus pseudintermedius*, *Vet*
586 *Dermatol* 2012, **23**: 276-82.

587 **Figure Legends**

588 **Figure 1. Phylogenetic relationships and resistance and genomic features.** The phylogenetic
589 relationship of the *S. pseudintermedius* genomes based on SNP clustering is shown at the top of
590 each figure. Strain names are coloured according to their phenotypic group, MSSP = light blue,
591 MDR-MSSP = dark blue, MRSP = pink, MDR-MRSP = red. Grey or coloured bars indicate
592 phenotypic resistance or presence of genetic marker, whilst white indicates susceptibility or
593 absence. A) Phenotypic antibiotic resistance profiles and genetic resistance markers MGEs of
594 the same type integrated at the same chromosomal loci unless stated. *SCCmecA* elements are
595 *SCCmecII-III* (grey), *SCCmecV(T)* (blue), *SCCmecIV* (yellow) and a unique *SCCmec* (green), with
596 homology to *SCCmecX* and *SCCmecV*; structural differences are shown in Figure 4. Tn5405-like
597 elements carried *aphA3-sat-aadE-ermB-dfrG* (grey), *aphA3-sat-aadE-ermB* (blue), *aphA3-sat-*
598 *aadE* (yellow) or *aphA3-sat-aadE-cat* (green); structural differences are shown in Figure 5. All
599 Tn5801 carried *tetM*. All Tn916 carried *tetM* but were integrated into three different sites on
600 the genome (1, 2 or 3). All Tn552 and Tn554-like carried *blaZ*. All IS256 and IS1272 carried *aac-*
601 *aph*. All IS431 carried *cadA*. SNPs associated with antimicrobial resistance to fluoroquinolones
602 (*gyrA* and *griA*) and fusidic acid (*fusA*). B) Content of other factors influencing fitness, survival
603 and horizontal gene transfer (HGT). MGEs of the same type integrated at the same
604 chromosomal loci unless stated. Three SpPI1 variants (grey, blue, yellow), two bacteriophage
605 phi1 variants (grey, blue) and three phi3 variants (grey, blue, yellow) were detected. Genes

606 encoding surface proteins, exoenzymes, toxins and regulatory systems are indicated. Barriers to
607 horizontal gene transfer (HGT) were restriction-modification (R-M) or clustered regularly
608 interspaced short palindromic repeats (CRISPR) systems. Two *hsdS* variants of type I R-M core
609 were detected (grey, blue). This figure appears in colour in the online version of JAC and in
610 black and white in the print version of JAC.

611 **Figure 2. Population structure of *Staphylococcus pseudintermedius*.** Clusters of related STs and
612 individual unlinked STs within the entire *S. pseudintermedius* MLST database are shown as an
613 eBURST diagram. Clusters of linked STs (black lines) correspond to clonal complexes (CCs). STs
614 for which MRSP phenotypes are reported in the MLST database are highlighted in black boxes.
615 STs for which genomes have been sequenced are highlighted in boxes as follows, light blue =
616 MSSP, dark blue = MDR-MSSP, pink = MRSP, red = MDR-MRSP. This figure appears in colour in
617 the online version of JAC and in black and white in the print version of JAC.

618 **Figure 3. Pairwise comparison of representative *Staphylococcus pseudintermedius* genomes.**
619 The alignment of genome sequences from ED99, 69687, 23929, 1726 and HKU10-03 are
620 displayed in Artemis Comparison Tool. Red bars present orthologue matches identified by
621 FASTA analysis. Mobile genetic elements (MGEs) including Staphylococcal cassette
622 chromosome (SCC)*mec* elements, transposons, plasmids, prophages and *S. pseudintermedius*
623 pathogenicity islands (SpPIs) are shown as coloured boxes. This figure appears in colour in the
624 online version of JAC and in black and white in the print version of JAC.

625
626 **Figure 4. Comparison of SCC*mec* elements from *Staphylococcus pseudintermedius* genomes.**
627 The SCC*mec*II-III element from ST71 (69687) is compared to SCC*mec*IV from ST261 (1726), and

628 SCC*mecV*(T) from ST68 (23929). Homology is indicated by a colour scale of blue (100%
629 homology) to grey (78% homology). Genes are coloured by function *mecA* in red, *mecRI* in pink,
630 *ccr* in yellow, type I restriction-modification (R-M) system genes in blue, type II R-M system
631 genes in light blue, and clustered regularly interspaced short palindromic repeat (CRISPR)
632 system genes in green. Figure produced using EasyFig and using SCC*mecII-III* element sequence
633 from 69876*. This figure appears in colour in the online version of JAC and in black and white in
634 the print version of JAC.


635 **Figure 5. Comparison of *Tn5405*-like elements from *Staphylococcus pseudintermedius***
636 **genomes.** The *Tn5405*-like element from ED99 is compared to *Tn5405*-like elements from 1726,
637 E140, 69687, 23929, GL118B and GL117B. Homology is indicated by a colour scale of blue (100%
638 homology) to grey (89% homology). Genes are coloured by function transposase in red,
639 antibiotic resistance genes in yellow, topoisomerase genes in green, resolvase genes in light
640 green, plasmid replication genes in bright blue and plasmid recombination genes in dull blue.
641 Genes in grey were not homologous to any genes using BLAST. *aphA*, *aadE* encode resistance to
642 aminoglycosides, *sat* to streptothricin, *dfrG* to trimethoprim and *cat* to chloramphenicol. Figure
643 produced using EasyFig and *Tn5405*-like element sequence from 69876*. This figure appears in
644 colour in the online version of JAC and in black and white in the print version of JAC.

645 **Figure S1. Comparison of representative prophage from *Staphylococcus pseudintermedius***
646 **strains.** A representative prophage from each of the 8 insertion sites is shown. Homology is
647 indicated by a colour scale of blue (100% homology) to grey (84% homology). The prophages are

648 named by insertion site (ϕ X) and then the genome from which the sequence originates. Figure
649 produced using EasyFig.

650 **Figure S2. Comparison of SpPI1 from *Staphylococcus pseudintermedius* strains.** The
651 pathogenicity island SpPI1 from ED99 is compared to SpPI1 elements from other sequenced *S.*
652 *pseudintermedius* strains. Homology is indicated by a colour scale of blue (100% homology) to
653 grey (84% homology). SpPI1 genes are coloured pink, and integrase genes in red. Gene names
654 are shown for genes that were homologous to annotated genes by pBLAST. Figure produced
655 using EasyFig. *Note that *Tn5405*-like elements sequence from BNG1 and 69876 was used to
656 create the figure.

Figure 1
A



B






Figure 2



658

659

Figure 3




660

661

662


663 **Figure 4**



664

665

666 **Figure 5**



667

Strain	Phenotypic group	Country/ year/ isolation site	Phenotypic Resistance profile	Nº Ab classes resistance	MLST	Total Yield Kb (~ fold coverage)	Number of contigs	Genome size (bp)	GC content	CDS number	GenBank Accession
69687	MDR-MRSP	UK/ 2012/skin	OXA-PEN-AMP-AMC-CL-GEN-KAN-ERY-CLI-SXT-CIP	7	71	346678 (128x)	130	2,712,000	37.4%	2,651	ERR163420
69876	MDR-MRSP	UK/ 2012/ear	OXA-PEN-AMP-AMC-CL-GEN-KAN-ERY-CLI-SXT-CIP	7	71	407664 (150x)	135	2,711,724	37.4%	2,695	ERR144842
HH15	MDR-MRSP	Germany/ 2012/skin	OXA-PEN-AMP-AMC-CL-GEN-KAN-ERY-CLI-TET-SXT-CIP	7	71	592337 (213x)	160	2,780,805	37.3%	2,747	ERR144844
GL119A	MDR-MRSP	Germany/ 2012/skin	OXA-PEN-AMP-AMC-CL-GEN-KAN-ERY-CLI-SXT-CIP	7	71	395970 (144x)	147	2,749,309	37.4%	2,784	ERR294366
GL151A	MDR-MRSP	Germany/ 2012/wound	OXA-PEN-AMP-AMC-CL-GEN-KAN-ERY-CLI-TET-SXT-CIP	7	71	359894 (131x)	156	2,753,286	37.3%	2,741	ERR294367
23929	MDR-MRSP	Ireland/ 2008/skin	OXA-PEN-AMP-CL-KAN-ERY-CLI-TET-SXT-CIP	7	68	322943 (118x)	157	2,742,394	37.3%	2,739	ERR175868
1726	MDR-MRSP	UK/ 2007/ear	OXA-PEN-AMP-KAN-ERY-TET-SXT	5	261	312702 (120x)	120	2,612,150	37.5%	2,568	ERR144810
BNG1	MRSP	UK/ Apr2011/skin	OXA-PEN-AMP-CL-TET	2	260	378309 (142x)	113	2,659,338	37.3%	2,608	ERR144839
BNG3	MRSP	UK/ Sep2011/skin	OXA-PEN-AMP-CL-TET	2	260	395712 (150x)	160	2,646,594	37.4%	2,597	ERR144767
GL117B	MDR-MSSP	Germany/ 2012/ear	PEN-AMP-KAN-ERY	3	263	419305 (166x)	148	2,532,911	37.6%	2,488	ERR310922
GL118B	MDR-MSSP	Germany/ 2012/skin	PEN-AMP-KAN-TET	3	262	454726 (180x)	117	2,527,818	37.6%	2,467	ERR310921
463949	MSSP	USA/ 2012/skin	PEN-AMP-TET	2	309	425893 (169x)	76	2,523,489	37.6%	2,463	ERR294364
ED99	MDR-MSSP	UK/ 2005	PEN-AMP-KAN-ERY-TET-SXT	5	25	-	-	2,572,216	37.6%	2,401	NC_017568
HKU10-03	MSSP	China/ unknown	unknown	-	308	-	-	2,617,381	37.5%	2,451	NC_014925
E140	MDR-MRSP*	Denmark/ 2009	unknown	-	71	-	-	2,769,458	38.0%	2,678	ANOI01000001
MEAN	-	-	-	-	-	401011 (151x)	135	2,660,725	37.48%	2,605	

668

669 **Table 1:** Antimicrobial resistance and general genome characteristics of sequenced *Staphylococcus pseudintermedius*. All *S.*
670 *pseudintermedius* strains originate from clinical infections. For each isolate and genome, the phenotypic group, country origin and
671 year of isolation, resistance phenotype, number of antimicrobial classes the isolate is resistant to, 7-gene multilocus sequence type
672 (MLST)(54), total yield, fold coverage, number of contigs assembled, genome size, GC contents and number of coding domain
673 sequences (CDS) are shown. MSSP: phenotypic susceptibility to oxacillin and *mecA*-negative, and resistant to antimicrobials in <3
674 antimicrobial classes. MRSP: phenotypic resistance to oxacillin and *mecA*-positive, and resistant to antimicrobials in <3 antimicrobial
675 classes. MDR-MSSP: phenotypic susceptibility to oxacillin and *mecA*-negative, and resistant to antimicrobials in ≥ 3 antimicrobial
676 classes. MDR-MRSP: phenotypic resistance to oxacillin and *mecA*-positive, and resistant to antimicrobials in ≥ 3 antimicrobial classes.
677 OXA: oxacillin. PEN: penicillin. AMP: ampicillin. AMC: amoxicillin/clavulanate. CL: cefalexin. GEN: gentamicin. KAN: kanamycin. ERY:
678 erythromycin. CLI: clindamycin. TET: tetracycline. SXT: Trimethoprim/sulfamethoxazole. CIP: ciprofloxacin. RIF: rifampicin. All
679 phenotypic resistances could be putatively assigned to a genetic determinant in all isolates. *Phenotype not published but assumed
680 based on ST71.²⁶

681

682

683

684